Ameritas Investment Partners
PRME icon

Ameritas Investment Partners’s Prime Medicine PRME Stock Holding History

Ameritas Investment Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31K Hold
8,407
– – ﹤0.01% 2531
2026
Q1 		$29.3K Buy
8,407
+2,506
+42% +$9.54K ﹤0.01% 2409
2025
Q4 		$20.5K Hold
5,901
– – ﹤0.01% 2630
2025
Q3 		$32.7K Buy
5,901
+2,000
+51% +$8.13K ﹤0.01% 2439
2025
Q2 		$9.63K Hold
3,901
– – ﹤0.01% 2992
2025
Q1 		$7.76K Hold
3,901
– – ﹤0.01% 2890
2024
Q4 		$11.4K Hold
3,901
– – ﹤0.01% 2868
2024
Q3 		$15.1K Hold
3,901
– – ﹤0.01% 2775
2024
Q2 		$20.1K Hold
3,901
– – ﹤0.01% 2612
2024
Q1 		$27.3K Hold
3,901
– – ﹤0.01% 2440
2023
Q4 		$34.6K Hold
3,901
– – ﹤0.01% 2344
2023
Q3 		$37.2K Buy
3,901
+634
+19% +$8.23K ﹤0.01% 2254
2023
Q2 		$47.9K Buy
3,267
+2,436
+293% +$34K ﹤0.01% 2080
2023
Q1 		$10.2K Hold
831
– – ﹤0.01% 2719
2022
Q4 		$13.9K Buy
+831
New +$15K ﹤0.01% 2701

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ameritas Investment Partners's PRME Position: Q2 2026 in Review

Ameritas Investment Partners held its Prime Medicine (PRME) position steady in Q2 2026 at 8,407 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #2531.

Ameritas Investment Partners first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $47.9K in Q2 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Ameritas Investment Partners held 8,407 shares of Prime Medicine worth $31K as of Q2 2026.
  • Ameritas Investment Partners left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2531 holding.
  • Ameritas Investment Partners first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Ameritas Investment Partners's Prime Medicine position peaked at $47.9K in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.